Definitive Contract 75N93025C00034
Award Date
9/23/25
Potential Completion Date
9/22/30
Potential Value
$2.2M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Medigen, Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Frederick, MD 21701, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
27
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Medigen, Inc., a biotechnology company specializing in vaccine development. The $815,000.00 contract is for laboratory and testing services. Medigen has previously received grants from NIAID totaling over $4 million to support R&D on novel live-attenuated vaccines. This contract does not have a...
This is a $27,042,695.21 federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to Thomas Jefferson University for the advanced development of multivalent vaccine candidates for filovirus (e.g. Ebola) and Lassa fever. The contract does not have a set-aside designation. The contract involves the development, testing, and manufacturing of vaccine candidates, including Rabies Virus Based Platform Vaccines...
This is a firm fixed price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Medigen, Inc., a biotechnology company that specializes in vaccine research, development, and manufacturing. The contract is for the production of Virus-Like Particles (VLPs) and has a total ceiling value of $28,280.00. This contract does not have a set-aside designation. Medigen, Inc. has previously...
This is a $26,413,819.97 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Auro Vaccines LLC, a foreign-owned for-profit organization, for the advanced development of multivalent vaccine candidates for filoviruses and Lassa fever. The 6-year contract, which does not have a set-aside designation, will support vaccine development and manufacturing work performed in Baltimore, Maryland, with a completion...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $30,940.00 firm-fixed-price purchase order contract to Zalgen Labs LLC, a small business biotechnology company, for the delivery of 23 units of ReLASV Pan-Lassa NP (2 plate kit) ELISA kits. This sole-source contract was awarded under the authority of FAR 13.106-1(b) for procurement where there is only one responsible source. The contract supports NIAID's research and testing related to infectious diseases like Lassa...
This is a delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is valued at $13,618,140.00 and has a period of performance through September 14, 2028. It is a cost-plus-fixed-fee contract type. The contract supports NIAID's mission, which includes research and development of vaccines and...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute, a component of the National Institutes of Health within the Department of Health and Human Services. The contract, valued at $89,871, was awarded to Medigen, Inc., a biotechnology company that specializes in vaccine development and manufacturing. The contract has a firm fixed price pricing type and an ultimate completion date of May 30, 2010. Medigen has received numerous federal grants...
This is a $22,480,551.95 cost-plus-fixed-fee contract awarded by the Defense Threat Reduction Agency (DTRA) to Primmune Therapeutics, Inc. for the development of an oral broad-spectrum antiviral TLR7 agonist for the treatment of Lassa fever. The contract was awarded on January 30, 2024 and has an ultimate completion date of December 25, 2026. This contract was not set aside for any specific business type. The contract originated from a Broad Agency Announcement (BAA) solicitation issued by DTRA,...
This is a $30,320,960.00 delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The contract is for the establishment of mRNA vaccine capability in support of NIAID's Vaccine Research Center (VRC) programs. The contract is a cost-plus-fixed-fee type with a period of performance through June 17, 2030. There is no set-aside...
This is a $162,950,791.20 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian federal agency, to Leidos, Inc. Research And Development Division. The contract is for biomedical (basic) research and development services, and does not have a set-aside designation. The contract is associated with larger contract vehicles, including the One Acquisition Solution for Integrated Services (OASIS) and Alliant II Governmentwide...